Topics

Clinical Trials About "launches open science Alzheimer initiative" RSS

02:04 EST 14th December 2019 | BioPortfolio

We list hundreds of Clinical Trials about "launches open science Alzheimer initiative" on BioPortfolio. We draw our references from global clinical trials data listed on ClinicalTrials.gov and refresh our database daily.

More Information about "launches open science Alzheimer initiative" on BioPortfolio

We have published hundreds of launches open science Alzheimer initiative news stories on BioPortfolio along with dozens of launches open science Alzheimer initiative Clinical Trials and PubMed Articles about launches open science Alzheimer initiative for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of launches open science Alzheimer initiative Companies in our database. You can also find out about relevant launches open science Alzheimer initiative Drugs and Medications on this site too.

Showing "launches open science Alzheimer initiative" Clinical Trials 1–25 of 13,000+

Relevant

Alzheimer's Disease Neuroimaging Initiative Grand Opportunity

The purpose of this study is to build upon the information obtained in the original Alzheimer's Disease Neuroimaging Initiative (ADNI1), to examine how brain imaging technology can be used with other tests to measure the progression of mild cognitive impairment (MCI) and early Alzheimer's disease (AD). ADNI-GO seeks to define and characterize the mildest symptomatic phase of AD, referred to in this study as early amnestic MCI (EMCI). This information will aid in the early detec...


Alzheimer's Disease Neuroimaging Initiative 3 (ADNI3) Protocol

Since its launch in 2004, the overarching aim of the Alzheimer's Disease Neuroimaging Initiative (ADNI) has been realized in informing the design of therapeutic trials in AD. ADNI3 continues the previously funded ADNI-1, ADNI-GO, and ADNI-2 studies that have been combined public/private collaborations between academia and industry to determine the relationships between the clinical, cognitive, imaging, genetic and biochemical biomarker characteristics of the entire spectrum of ...

The Ontario Neurodegenerative Disease Research Initiative

The Ontario Neurodegenerative Disease Research Initiative (ONDRI) is a province-wide collaboration studying dementia and how to improve the diagnosis and treatment of neurodegenerative diseases including: - Alzheimer's disease (AD) - Parkinson's disease (PD) - amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease) - frontotemporal lobar degeneration (FTD) - vascular cognitive impairment, resulting from stroke (VCI)


Safety and Efficacy of Next Science Gel on Toenail Fungus

This is a 52 week, 20-patient open-label pilot study on the safety and efficacy of Next Science Wound gel in the treatment of mild to moderate Distal Subungual Onychomycosis.

Improving STEM Outcomes for Young Children With Language Learning Disabilities

The sophisticated language of science can be a barrier to Science, Technology, Engineering, and Math (STEM) learning, especially for children who have specific language impairment (SLI). The purpose of this randomized controlled trial is to test vocabulary and grammar interventions embedded in a small-group inquiry-based science instruction for their potential to ameliorate language deficits that impede science learning. Participants will be 54 kindergartners with SLI. Proximal...

Open-Label Trial of Medical Marijuana for the Treatment of Behavioral Symptoms in Older Adults With Alzheimer's Dementia

This is an open label, ten week, clinical trial of a proprietary high CBD/low THC sublingual solution (20mg/ml CBD and 0.58mg/ml THC) for the treatment of clinically significant anxiety and agitation in mild to moderate Alzheimer's Disease.

Assessment of the Improvement of Wound Healing Rate and Wound Bioburden With the Combination of Next Science Wound Gel and Wash

This is a 12-week, single-site, open-label prospective study in adult with a chronic wound diagnosis. Subjects will be randomized in equal numbers to either the control treatment arm, antimicrobial control treatment arm, or Next Science treatment arm and will receive this treatment until the wound is completely healed or they are exited from the study. Subjects will have a weekly in-office debridement visit for up to 12 weeks.

Safer Care for Older People in (Residential) Environments

The overall aim of the program is to advance knowledge translation science in order to improve clinical and staff related outcomes in long term care facilities (nursing homes) in western Canada. SCOPE will assess the effect of Care Aide led Quality Improvement efforts on staff quality of work life as well as resident quality of care. A key element of SCOPE is a leadership development stream which introduces complexity science and education on quality improvement which aims to s...

Continued Safety Monitoring of Solanezumab in Alzheimer's Disease

This study is an open-label extension study in Alzheimer's patients who have completed participation in either solanezumab Clinical Trial H8A-MC-LZAM or H8A-MC-LZAN.

Clinical Assessment of Next Science Wound Gels in Healing Below the Knee Amputation Surgical Wound Compared to SOC

This is a 64-patient, 90-day, open -label study on adult patients undergoing below knee amputation for various etiologies. The objective of this study is to assess surgical wound healing and wound bioburden using combination treatment of Next Science SurgX™ Antimicrobial Wound Gel and BlastX™ Antimicrobial Wound Gels as compared to standard of care.

Open Label Study of TRx0014 in Alzheimer's Disease

This is an open label, dose-ranging study of two doses of TRx0014 in patients with mild or moderate Alzheimer's Disease. The trial is made available to any patient ongoing on treatment in the clinical trial designated TRx-014-001 at termination of that study. Treatment for each individual patient will continue for as long as the treating physician feels there is benefit to the patient. This current protocol covers each patient for 12 months in the first instance.

Feasibility and Effects of Valaciclovir Treatment in Persons With Early Alzheimer's Disease

This study investigates the effects of Valaciclovir treatment to individuals with Alzheimer's disease or Mild Cognitive Impairment of Alzheimer's Disease Type. It is an open pilot trial where 36 participants will receive 4 weeks of Valaciclovir treatment. Participants will be investigated using different measures before and after the treatment period.

Dominantly Inherited Alzheimer Network (DIAN)

The purpose of this study is to identify potential biomarkers that may predict the development of Alzheimer's disease in people who carry an Alzheimer's mutation.

A Study in Semagacestat for Alzheimer's Patients

The primary objective of the study is to assess the safety of Semagacestat in Alzheimer's disease (AD) patients during 24 months of open-label treatment. Baseline for the efficacy measures is defined as prior to the initial treatment period in studies LFAN and LFBC. For all safety analyses, baseline for patients will be week 0 of LFBF.

The Alzheimer's Disease THErapy With NEuroaid (ATHENE) Study

MLC601 (Neuroaid) is a Traditional Chinese Medicine (TCM) having neuroprotective and neuroproliferative properties in cellular and animal models of brain injury. It contains 9 herbal and 5 non-herbal components. MLC901 (Neuroaid II), a simplified formula of MLC601, containing only the 9 herbal components yet showing the same efficacy has become available. This study is carried out to find out if NEUROAID II (MLC901) is safe to be taken together with other established medicines...

Open-Label Extension Study of 23 mg Donepezil SR in Patients With Moderate to Severe Alzheimer's Disease

The purpose of this study is to evaluate the safety and efficacy of long-term administration of 23 mg donepezil sustained release (SR) in patients with moderate to severe Alzheimer's disease. Patients who complete study E2020-G000-326 with no ongoing serious adverse events (SAEs) and no serious adverse drug reactions will be eligible to enter the open-label extension study.

Study of Daratumumab in Patients With Mild to Moderate Alzheimer's Disease

This is an open-label, pilot study designed to explore whether daratumumab may have a clinically meaningful effect in patients with mild to moderate Alzheimer's disease.

The Goals of Care Initiative

A single site hybrid implement-evaluation stepped wedge cluster randomised controlled trial in which cancer cluster groups (lung, colorectal, breast, renal, ovarian, upper GI & sarcoma) are randomised sequentially to initiate the Goals of Care Initiative into clinical practice.

EARTH 413: A Study of Aricept in Hispanic Patients With Mild to Moderate Alzheimer's Disease (AD)

12-week, open-label study to evaluate the effectiveness and safety of donepezil hydrochloride in Hispanic patients with mild to moderate Alzheimer's Disease (AD) in the U.S.

Next Science Antimicrobial Mouth Rinse Study

To assess the effect of a test antimicrobial oral rinse from Next Science on the prevention of oral biofilm formation and thereby preventing gingivitis by monitoring the oral microbial flora and measuring gingival inflammation and bleeding.

Study of Memantine in Assessment of Selected Measures of Volumetric Magnetic Resonance Imaging (MRI) and Cognition in Moderate AD (Alzheimer's Disease)

The purpose of this study is to characterize the progression of disease using volumetric MRI techniques and cognitive outcome measures in patients with moderate dementia of the Alzheimer's type treated with open-label memantine.

Open-Label Extension of the Phase III Study With Tramiprosate (3APS) in Patients With Mild to Moderate Alzheimer's Disease

The purpose of this Phase III open-label extension study is to evaluate the long-term safety of Tramiprosate (3APS) in patients with mild to moderate Alzheimer’s disease.

Open-label, PK and Safety Study in Mild-to-moderate Alzheimer's Disease Patients

This is a Phase 2a, multi-center, open-label study of PTI-125 in mild-to-moderate AD patients, 50-85 years of age. A total of twelve (12) patients will be enrolled into the study. Patients will receive 100 mg b.i.d. of PTI-125. The objectives of this study are to investigate the safety, pharmacokinetics and effect on biomarkers of PTI-125 following 28-day repeat-dose oral administration.

Alzheimer and Sleep

The aim of the study is the analysis of two inhibitors of Ach-E: galantamine and donépézil in over 65 years' old patients suffering from Alzheimer disease (MMSE between 20 and 26) without Alzheimer's medication.

A 24 Week, Multicenter, Open, Evaluation of the Clinical Effectiveness of the Once-daily 10 cm2 Rivastigmine Patch Formulation in Patients With Probable Alzheimer's Disease (EXTRA)

This study is designed to confirm the efficacy, the tolerability, the patient compliance and the caregiver satisfaction with rivastigmine target patch size 10 cm2 in patients with probable Alzheimer's Disease (Mini-Mental State Examination 10-26) in the community setting


More From BioPortfolio on "launches open science Alzheimer initiative"

Quick Search